About Us

Skip Navigation LinksAbout Us > Faculty & Staff > Faculty > Nadine Hempel
Nadine Hempel

Assistant Professor of Nanobioscience

Education:

  • Post-doctoral Fellow, Department of Immunology and Microbial Diseases, Albany Medical College, Albany, NY, 2007-2010
  • Post-doctoral Fellow, Department of Hematology and Cancer Biology, Duke University Medical Center, Durham, NC, 2004-2007
  • Ph.D., Pharmacology, School of Biomedical Sciences, University of Queensland, Brisbane, Australia, 2004
  • B.Sc.(Hons), Physiology & Pharmacology, University of Queensland, Brisbane, Australia, 1999

Past Professional Experience:

  • Senior Research Scientist, College of Nanoscale Sciences and Engineering, University at Albany (SUNY), Albany, NY, 2011
  • Research Assistant Professor, Department of Immunology and Microbial Diseases, Albany Medical College, Albany, NY, 2010-2011

Areas of Research:

  • Cancer Cell Metastasis
  • Antioxidant Enzymes, Reactive Oxygen Species and Signal Transduction
  • Ovarian and Bladder Cancer 
  • Nanobiotechnology
  • Tumor Cell Migration and Invasion

Research Description:

Our primary research goal is to understand the molecular mechanisms that regulate tumor cell metastasis. Movement of cancer cells from the primary tumor to distant metastatic sites represents the most lethal stage of cancer progression, due to difficulties in detection, isolation and effective targeted treatment of these lesions. Metastatic progression depends on a multitude of signaling pathways, understanding of which will result in discovery of novel metastatic tumor markers and for the development of anti-metastatic therapies. Specifically, we are investigating the role that reactive oxygen species, antioxidant enzymes and the mitochondria play in metastatic progression of ovarian and bladder cancer. Based on this knowledge we are interested in utilizing innovative nano-scale diagnostic and analytical tools to isolate and characterize metastatic tumor cells, and to apply nano-scale therapeutic delivery methods to target and treat metastatic disease.

Recent Honors and Awards:

  • National Cancer Institute (NIH) Pathway to Independence Award (K99/R00; 2010)
  • Young Investigator Award, Society for Free Radical Biology and Medicine (2008 & 2010)
  • American Association for Cancer Research Scholar-in-Training Award (2010)
  • National Cancer Institute (NIH) Ruth L. Kirschstein National Research Service Awards (NRSA; 2008)

Selected peer-reviewed publications:

McCarthy DA, Ranganathan A, Subbaram S, Flaherty NL, Patel N, Trebak M, Hempel N, Melendez JA (2013) Redox-control of the alarmin, Interleukin-1α. Redox Biology. 1(1):218-25. PMC3757693

Hempel N, Bartling TR, Mian B, Melendez JA (2013) Acquisition of the metastatic phenotype is accompanied by H2O2-dependent activation of the p130Cas signaling complex. Molecular Cancer Research, 11(3):303-12.

Uusitalo LM, Hempel N (2012) Recent Advances in Intracellular and In vivo ROS Sensing: Focus on Nanoparticle and Nanotube Applications. International Journal of Molecular Sciences. 13(9):10660-79.

Hempel N, Carrico PM, Melendez JA (2011) Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events that Drive Metastasis Anti-Cancer Agents in Medicinal Chemistry, 11(2):191-201.

Lee JD, Hempel N, Lee NY, Blobe GC (2010) The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenisis, 31(2):175-83.

Hempel N, Ye H, Abessi B, Mian B, Melendez JA (2009) Altered redox status accompanies progression to metastatic human bladder cancer. Free Radical Biology & Medicine, 46(1):42-50.

Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC (2008) Expression of the Type III TGF-β Receptor is negatively regulated by TGF-β. Carcinogenesis, 29(5):905-12.

Conner K, Hempel N, Nelson KK, Dabiri G, Gamarra A, Van De Water L, Mian B, Melendez JA (2007) Manganese Superoxide Dismutase enhances the invasive and migratory activity of tumor cells. Cancer Research, 67(21):10260-7.

Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC (2007) Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Research, 67(11):5231-8. Highlighted in Faculty of 1000 Medicine.

Turley RS, Finger EC, How T, Hempel N, Fields TA, Blobe GC (2007) The Type III Transforming Growth Factor-b Receptor as a Novel Tumor Suppressor Gene in Prostate Cancer. Cancer Research, 67(3):1090-8.

Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC (2007) The type III TGF-beta receptor suppresses breast cancer progression. Journal of Clinical Investigation, 117: 206-17.

For additional publications and up-to-date list:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Hempel+N

Book Chapters:

Hempel N (2012) Chapter 10: Receptor-based Biosensors: Focus on Olfactory Receptors and Cell-Free Sensors. The Nanobiotechnology Handbook. Ed. Xie Y (Taylor & Francis).

Carrico PM, Hempel N, Melendez JA (2009) Respiratory Control of Redox Signaling and Cancer. Cellular Respiration and Carcinogenesis. Ed. Apte SP and Sarangarajan R. (Humana Press, New York).

Hempel N, Barnett AC, Gamage N, Duggleby RG, Martin J, Windmill KF, McManus ME (2005) Human SULT1A Sulfotransferases. Human cytosolic sulfotransferases. Ed. Pacifici GM and Coughtrie MWH. (Taylor & Francis; London).

Member:

American Association for Cancer Research (AACR)
Society for Free Radical Biology and Medicine (SFRBM)

Recent Invited Talks and Conference Presentations:

  • SUNY Downstate Medical Center, Brooklyn NY, Dec 2013
  • SFRBM Annual Meeting, San Antonio TX, Nov 2013
  • University of Vermont, Burlington VT, Mar 2013
  • Capital Region Cancer Research New Frontiers Symposium: Nanotechnology in Cancer Research and Treatment, Nov 2012
  • SFRBM Annual Meeting - Professional Development Session, San Diego CA, Nov 2012